Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Sarcoma, Ewing 1Pathologic Complete Response 1Osteosarcoma 1Neutropenia 1Neoplasms 1Myelosuppression 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pegylated granulocyte colony-stimulating factor 2trilaciclib 1plerixafor 1eravacycline 1ceftolozane, tazobactam drug combination 1Piperacillin, Tazobactam Drug Combination 1PM 01183 1Loratadine 1Blood Specimen Collection 1Antiviral Agents 1Antifungal Agents 1Anti-Infective Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neutropenia × trilaciclib × Clear all
NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡